Ryvu Therapeutics Reports First Quarter 2021 Financial Results
News provided by
Share this article
Share this article
KRAKOW, Poland, May 12, 2021 /PRNewswire/ Ryvu Therapeutics (WSE: RVU) reported today its first quarter 2021 financial results and provided a corporate update. Q1 2021 was an eventful quarter for Ryvu and developments around RVU120 played a key role in it - commented Pawel Przewiezlikowski, Chief Executive Officer of Ryvu. We have submitted a clinical trial application to conduct a Phase I/II study of RVU120 in patients with solid tumors, and shortly after that we received an approval to expand the ongoing Phase I of RVU120 in AML and high risk MDS from US sites to Poland. We have also secured a non-dilutive grant to finance the RVU120 solid tumor study. Despite the recent partial clinical hold imposed on RVU120 Phase Ib study, we have achieved meaningful research progress in our clinical and pre-clinical pipeline in these first months of 2021. Patient safet
Łukasz Gągulski/PAP
Pfizer has announced that it will start delivering more doses of its vaccine to EU countries starting from April 26, Mateusz Morawiecki has said. Good news that has just reached URPL, WMiPB (Office for Registration of Medicinal Products, Medical Devices and Biocidal Products). Vaccine producer Pfizer announced that from April 26 it will start sending further doses to the European Union, the prime minister wrote on Facebook on Thursday. Altogether, we are to receive some 4.2 million doses of the Pfizer vaccine by June, added the prime minister. This is great news for our National Vaccination Programme which has just accelerated, wrote Morawiecki.
The Canadian pharmaceutical market is the 10th largest in the world. What are the biggest pharma stocks on the TSX and TSXV?
The Canadian pharmaceutical market is the 10th largest in the world and accounts for 2 percent of the global prescription drug market. But what are the biggest Canadian pharma stocks?
Many of the most successful Canadian drug companies are in the late stages of clinical trials, have brought pharmaceutical products to market or have partnered with other companies to develop and market products, both in Canada and globally. Interestingly, out of all the Group of Seven countries, Canada has the lowest production cost index in the pharmaceutical industry.
Share this article
HOUSTON, Feb. 18, 2021 /PRNewswire/ WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ( WPD ) and
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ( CNS or the Company ), biopharmaceutical companies specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that WPD Pharmaceuticals received a positive opinion of the Lower Silesian Medical Chamber Ethics Committee in Wrocław, Poland for its planned upcoming Berubicin clinical trial in adults with Glioblastoma Muliforme (GBM) under the WPD-201 Clinical Trial Protocol. CNS Pharmaceuticals has received study level Central IRB Approval from the Central IRB for the CNS-201 Clinical Trial Protocol.
Share this article
Share this article
LAVAL, QC, Dec. 30, 2020 /CNW/ Bausch Health Companies Inc. (NYSE/TSX: BHC) ( Bausch Health ), today announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection, 4 mg/ml, for the treatment of COVID-19 in adult and adolescent patients (12 years of age and older weighing at least 40 kg) who require oxygen therapy. DEXAVEN is a corticosteroid that reduces inflammation. We re pleased that Poland s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products has approved DEXAVEN for the treatment of symptoms due to COVID-19, because now patients in Poland have another treatment option to fight this virus, said Thomas J. Appio, president, Bausch + Lomb/International, Bausch Health. Bausch Health continues to evaluate our health care products and medicines around